Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
Julie Gralow: Mobile App Symptom Monitoring Helps Maintain Quality of Life in Advanced Cancer
oncodaily - Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, shared a post on X: “Use Of Mobile App For Proactive Symptom Monitoring Helped Patients With Advanced Cancer […]
AI Summary: A smartphone-based symptom monitoring program preserved quality of life for people with advanced cancer by enabling real‑time reporting and prompt clinician response. The intervention maintained patient function and well‑being compared with usual care, demonstrating a scalable, low‑cost way to keep symptoms under control — because yes, your phone can sometimes do what clinic schedules cannot.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
Short-term fasting could boost chemo response in ovarian cancer, study suggests
medicalxpress - A simple change in meal timing may help improve outcomes for women with the most common and aggressive form of ovarian cancer, a new study suggests.
AI Summary: ASCO‑presented research indicates short‑term fasting around chemotherapy cycles can enhance response in high‑grade serous ovarian cancer versus a regular diet, altering tumor biology to increase chemosensitivity. The findings suggest a low‑cost adjunct to standard treatment, though real‑world feasibility and longer‑term benefits require larger trials — fasting as a potential therapeutic booster, not a fad.